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LETTERS TO THE EDITOR
Calcium Channel Blockers and
Drug Interactions
Wayne ( I) concluded that it may be preferable to use diltiazem
in combination with beta-adrenergic blocking agents. In contrast,
another study (2) of diltiazem with propranolol showed a deteri-
oration in exercise performance compared with either drug alone.
Further, the combination of diltiazem with a beta-blocker may
have a synergistic action, prolonging AV conduction with resultant
serious deleterious effects (3).
Diltiazem undergoes extensive hepatic metabolism, and inter-
action between the calcium channel blockers and drugs that alter
hepatic flow are an important consideration. Therefore, diltiazem
should be used with caution in patients with impaired renal or
hepatic function. Any drug that affects hepatic Row will undoubt-
edly alter the half-life and pharmacokinetics of the calcium block-
ers. A classic example of a drug that decreases blood flow to the
liver is cimetidine. Since both cimetidine and diltiazem are widely
used, this drug interaction is important to remember.
Recently published studies have shown an interaction between
calcium blockers and digitalis. Verapamil may displace digoxin
at cellular receptor sites, thereby increasing plasma concentrations
of digoxin and adding to the likelihood of digitalis toxicity. The
same effect was found after administration of nifedipine, although
to a lesser degree. The manufacturer warns that concomitant use
of diltiazem with digitalis may result in additive effect on con-
duction. Hence, the dose of digoxin should be halved in patients
taking calcium channel blockers.
Calcium channel blockers may also cause clinical problems in
patients taking diuretic drugs, prazosin or hydralazine. These pa-
tients require a very cautious approach because of possible undue
hypotension. Disopyramide should not be given within 48 hours
before or 24 hours after verapamil administration. Concomitant
use of disopyramide may result in negative interactions. It should
be borne in mind that disopyramide level does not even have to
be toxic. Combined verapamil and quinidine therapy should be
avoided, as this combination has resulted in episodes of ventricular
fibrillation and severe pulmonary edema.
Published reports (4) have revealed that interactions have oc-
curred with barbiturates, phenytoin, methyldopa and procainam-
ide. Potential applications for the use of the calcium blockers
include hypertension control, treatment of Raynaud's phenomenon
and treatment and prophylaxis of migraine. For physicians desiring
proper patient management, a knowledge of the clinical manifes-
tations of these interactions is essential.
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Ventricular Ectopic Activity in Severe
Heart Failure
Important observations not made explicitly by Wilson et al. (1)
call into question some of their conclusions regarding the relative
insignificance of ventricular ectopic rhythm. First. the exclusion
of patients with "sustained ventricular tachycardia" (undefined by
the authors, but presumably more than three successive premature
ventricular contractions at a rate exceeding 100 beats/min) and
those with syncope severely limits their conclusion that cardiac
mortality in severe heart failure is without independent relation to
ventricular ectopic activity. Second, if one presumes that those
with fi ve or more consecutive premature ventricular complexes or
39% of the 77 patients followed up by the authors are at greatest
risk for sudden death. it becomes apparent that the II patients
receiving procainamide and quinidine and constituting more than
one-third of those at greatest risk may have been protected from
sudden death if such therapy were effi cacious. thereby reducing
the apparent import of high levels of ventricular ectopic activity
as an independent predictor of sudden death. This presumes. how-
ever. that the II receiving antiarrhythmic therapy were. in fact,
those at highest risk and that their therapy significantly reduced
the level of ventricular ectopic activity, two presumptions not
assessable from the data presented by Wilson's group.
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Holter-Monitored Sudden Death
Lewis et al. ( I) appear to have overlooked the significance of
changes in cycle length immediately preceding the tachyarrhythmia
in at least 9 of their 12 patients. As in our patients (2), these
changes typically consist of R on T phenomenon in the wake of
a postectopic pause. This pause had most commonly been observed
after multiform, repetitive ventricular ectopic activity. Both the
pause and the mechanism of its production are theoretically im-
portant in the genesis of subsequent fatal arrhythmias. It may be
somewhat misleading. therefore, to state that "no consistent re-
